About milestone pharmaceuticals inc - MIST
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
MIST At a Glance
Milestone Pharmaceuticals, Inc.
1111 Dr. Frederik-Philips Boulevard
Montréal, Québec H4M 2X6
| Phone | 1-514-336-0444 | Revenue | 1.55M | |
| Industry | Pharmaceuticals: Major | Net Income | -63,058,000.00 | |
| Sector | Health Technology | Employees | 38 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MIST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 109.601 |
| Price to Book Ratio | 5.138 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.954 |
| Enterprise Value to Sales | 78.823 |
| Total Debt to Enterprise Value | 0.479 |
MIST Efficiency
| Revenue/Employee | 40,684.211 |
| Income Per Employee | -1,659,421.053 |
| Receivables Turnover | 0.441 |
| Total Asset Turnover | 0.016 |
MIST Liquidity
| Current Ratio | 8.006 |
| Quick Ratio | 7.96 |
| Cash Ratio | 7.58 |
MIST Profitability
| Gross Margin | 92.626 |
| Operating Margin | -4,041.721 |
| Pretax Margin | -4,101.10 |
| Net Margin | -4,078.784 |
| Return on Assets | -66.707 |
| Return on Equity | -229.653 |
| Return on Total Capital | -62.966 |
| Return on Invested Capital | -75.576 |
MIST Capital Structure
| Total Debt to Total Equity | 139.762 |
| Total Debt to Total Capital | 58.292 |
| Total Debt to Total Assets | 51.406 |
| Long-Term Debt to Equity | 138.213 |
| Long-Term Debt to Total Capital | 57.646 |